Ocrelizumab

Progressive MS treatment – what is next? 1:39
Progressive MS treatment – what is next?
Giancarlo Comi • 23 Mar 2022
Using DMTs beyond patients with active MS 3:14
Using DMTs beyond patients with active MS
Xavier Montalban • 29 Mar 2022
Differential efficacy of DMTs in patients with active and inactive MS 1:30
Differential efficacy of DMTs in patients with active and inactive MS
Xavier Montalban • 29 Mar 2022
Changes in the MS treatment landscape over the last 2 years 6:03
Changes in the MS treatment landscape over the last 2 years
Abhijit Chaudhuri • 22 Mar 2022
Real-world studies of CGRP monoclonal antibodies and gepants for migraine 5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang • 3 Apr 2022
Selecting treatment options for NMOSD 1:51
Selecting treatment options for NMOSD
Michael Levy • 3 Apr 2022
Deep learning can predict treatment response in patients with progressive MS 8:46
Deep learning can predict treatment response in patients with progressive MS
Jean-Pierre Falet • 22 Mar 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab 3:33
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab
Virginia Meca-Lallana • 28 Feb 2022
Impact of ocrelizumab disruption on RRMS 2:52
Impact of ocrelizumab disruption on RRMS
Kelly Cotchett • 25 Feb 2022
Characterizing real-world outcomes among COVID-19 vaccinated patients with MS 2:07
Characterizing real-world outcomes among COVID-19 vaccinated patients with MS
Namita Tundia • 25 Feb 2022
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs 1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara • 24 Feb 2022
Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
COVID-19 vaccination in patients with MS 7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani • 13 Oct 2021
Delaying MS treatment to boost COVID-19 vaccination effects 4:37
Delaying MS treatment to boost COVID-19 vaccination effects
Anat Achiron • 12 Oct 2021
COVID-19 cases in MS patients receiving IV therapy 1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara • 14 Oct 2021
The content of VJNeurology is intended for healthcare professionals